The Clinical Research About the Therapeutic Effect and Safety of 10 Days Regimen With Single-agent of Decitabine for Elderly AML Patients
The outcome of the elderly AML patients is very poor. No obvious progress was achieved in
this field. Decitabine is a kind of specific DNA methylation shift enzyme inhibitor. It can
reverse the DNA methylation and induce the differentiation and apoptosis of the tumor cells.
Recent studies about decitabine in the treatment for elderly AML patients had achieved
inspiring results and indicated that low dose decitabine maybe a good choice for elderly AML
patients. So in this research the investigators plan to evaluate the safety and the
therapeutic effect of decitabine in the treatment of elderly AML patients.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Complete response rate after induction chemotherapy with decitabine
21 days after the induction chemotherapy
Jianxiang Wang, MD
Institute of Hematology, Hospital of Blood Disease, Chinese Academy of Medical Sciences
China: Food and Drug Administration